Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
Owlet’s push comes as parents demand smarter, more dependable nursery tech
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Subscribe To Our Newsletter & Stay Updated